GlassScriptPhysician profile
Eiman Firoozmand
NPI 1053322719
$5,855.54
in general payments reported to CMS, 2019-2025
15 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,269 · 2020: $382 · 2021: $1,322 · 2022: $517 · 2023: $394 · 2024: $825 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308 · Education: $57.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.78 |
| Education | $57.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,841.03 | 2019-2024 | Da Vinci Surgical System |
| Prescient Surgical | $272.28 | 2019-2020 | |
| Abbvie INC. | $246.80 | 2024-2025 | |
| Alkermes, INC. | $230.91 | 2019-2024 | Lybalvi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.63 | 2021 | |
| Ferring Pharmaceuticals INC. | $214.63 | 2019-2023 | Rebyota |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.93 | 2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $140.49 | 2024 | Invega Sustenna, Invega Trinza |
| Ethicon US, LLC | $134.38 | 2021 | |
| Boston Scientific Corporation | $130.02 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $115.80 | 2023 | Austedo Xr |
| Innocoll Pharmaceuticals Limited | $98.21 | 2022 | |
| Aroa Biosurgery Incorporated | $24.33 | 2025 | |
| Acell, INC. | $23.35 | 2019 | |
| Medtronic, INC. | $18.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eiman Firoozmand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.